← All trials
NCT03472963
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2018
- Primary completion
- Jan 15, 2019
- Completion date
- Jan 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 58
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityReponsible party - principal investigator
- Emory UniversityOverall official - principal investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.